SLC29A1 and cholangiocarcinoma: ENT-1 expression and subcellular localization may predict the degree of response to this drug in CCA and advanced BTC, as treated patients harboring ENT-1 on the tumor cell membrane had longer disease-free survival compared with patients lacking ENT-1 or expressing this protein, but failing in its targeting to the plasma membrane of tumor cells [16,17].